We evaluated whether concurrent glucagon-like peptide-1 receptor agonist (GLP-1 RA) plus sodium-glucose cotransporter 2 inhibitor (SGLT2i) use before solid-organ transplantation was associated with post-transplant outcomes in adults with obesity and type 2 diabetes. This evidence concerns the gene SLC5A2 and obesity disorder.